A Phase 2 interventional study of NPC-14 and Placebo in Muscular Dystrophy, Duchenne, sponsored by Kobe University. Status unknown at 4 sites in Japan. Open to male participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2015-09-03.
Sponsored by Kobe University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Dystrophy, Duchenne with a site in Japan — 2 open to participants now, 9 under way, 4 of them phase 3. Muscular Dystrophy, Duchenne · Japan.
Among the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan, this one is the 18th largest by planned enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2013, is one of 8 in phase 2, and was the 6th registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →2 of the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan are open now. Recruiting first, the newest first:
NS Pharma, Inc. · Sites in Japan, United States, Australia and 4 more countries
Men only
Sarepta Therapeutics, Inc. · Sites in Japan, United States, Belgium and 6 more countries
Men only
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 4 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 12 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 21 is below the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 62 across the 26 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 27 have an industry lead sponsor. The 10 most frequent:
Kobe University is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Kobe University has 1 study filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
4 of the studies in Muscular Dystrophy, Duchenne with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT04433234Daiichi Sankyo Co., Ltd.Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | 2027-01-31 |
| NCT05996003NS Pharma, Inc.NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | 2027-02-26 |
| NCT05135663Nippon Shinyaku Co., Ltd.Extension Study of NS-089/NCNP-02 in DMD | 2027-04-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Dystrophy, Duchenne with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Duchenne Muscular Dystrophy (DMD) is inherited neuromuscular disorders due to mutation in the gene that encodes critical muscle protein called dystrophin. Currently, there is no effective treatment option for the disease. A pharmacological approach by promoting mRNA translation regardless of the presence of premature stop codons by nonsense mutation, called the readthrough strategy, has been developing recently for DMD with nonsense mutation. NPC-14 is a candidate compound for the readthrough strategy, since effective readthrough activities were demonstrated in nonclinical studies. This study is a phase II study designed to assess safety, tolerability, and efficacy of NPC-14 in ambulant DMD patients with nonsense mutation that were confirmed by whole genome analysis. These goals will be accomplished by monitoring adverse events by physical examination, cardiac, pulmonary, auditory, balance, and laboratory tests as safety endpoints, and dystrophin expression in muscle biopsy as primary efficacy endpoint, muscle function (NSAA, timed test, muscle strength (QMT, MMT) , dairy activities by lifecorder), and biomarkers as secondary efficacy endpoints. The study is a randomized, double blind, placebo-controlled study in 21 DMD patients. After screening, eligible patients are allocated dynamically to weekly NPC-14 or a placebo (saline) in a 2:1 ratio and will receive study drugs for 36 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To meet the following criteria at screening (baseline visit), within 30 days prior to the first dose of study drug
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
Drug: NPC-14
Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
Drug: Placebo
NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist. * An initial dose of NPC-14 will be half of that calculated by distribution volume:Vd based on patient age for safety reason. * After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14
Also known as: Arbekacin
Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
Safety and tolerability (Adverse events)
Time frame: Up to 38 weeks (36 weeks treatment period and 2 weeks follow up period)
Change of dystrophin expression rate in muscle tissues from the baseline assessment
Time frame: At 37 weeks (1 week after from 36 weeks treatment period)
North Star Ambulatory Assessment
Time frame: At 36 weeks
Timed test (6MWT, time to walk/run 10 meters, time to climb/descent four steps, time to rise from the floor)
Time frame: At 36 weeks
Muscle strength (MMT, QMT)
Time frame: At 36 weeks
Dairy activities
Time frame: At 36 weeks
Biomarkers (CK, ALD)
Time frame: At 36 weeks
The record gives a start of Aug 2013, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arbekacin
Muscular Dystrophy, Duchenne →
Kobe University